Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities
Seminars in Cancer Biology · 2024-01 · 98 · 19-30
DOI: 10.1016/j.semcancer.2023.11.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2024-01. Verfasst von Claire Beckers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Tumor Hypoxia, Neoplasms. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 243 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Horizon 2020 Framework Programme, Horizon 2020.
Abstract (Originalsprache)
Hypoxia in solid tumors is an important predictor of poor clinical outcome to radiotherapy. Both physicochemical and biological processes contribute to a reduced sensitivity of hypoxic tumor cells to ionizing radiation and hypoxia-related treatment resistances. A conventional low-dose fractionated radiotherapy regimen exploits iterative reoxygenation in between the individual fractions, nevertheless tumor hypoxia still remains a major hurdle for successful treatment outcome. The technological advances achieved in image guidance and highly conformal dose delivery make it nowadays possible to prescribe larger doses to the tumor as part of single high-dose or hypofractionated radiotherapy, while keeping an acceptable level of normal tissue complication in the co-irradiated organs at risk. However, we insufficiently understand the impact of tumor hypoxia to single high-doses of RT and hypofractionated RT. So-called FLASH radiotherapy, which delivers ionizing radiation at ultrahigh dose rates (> 40 Gy/sec), has recently emerged as an important breakthrough in the radiotherapy field to reduce normal tissue toxicity compared to irradiation at conventional dose rates (few Gy/min). Not surprisingly, oxygen consumption and tumor hypoxia also seem to play an intriguing role for FLASH radiotherapy. Here we will discuss the role of tumor hypoxia for radiotherapy in general and in the context of novel radiotherapy treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: martin.pruschy@uzh.ch.
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Horizon 2020 Framework Programme
- Horizon 2020
- Horizon 2020 MSCA
Zitieren
APA
Beckers, C., Pruschy, M., & Vetrugno, I. (2024). Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Seminars in Cancer Biology, 98, 19-30. https://doi.org/10.1016/j.semcancer.2023.11.006
Vancouver
Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Seminars in Cancer Biology. 2024;98:19-30. doi:10.1016/j.semcancer.2023.11.006
BibTeX
@article{Beckers2024,
author = {Beckers, Claire and Pruschy, Martin and Vetrugno, Irene},
title = {Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities},
journal = {Seminars in Cancer Biology},
year = {2024},
volume = {98},
pages = {19--30},
doi = {10.1016/j.semcancer.2023.11.006}
}
EUVIMED